1
Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
Condition(s):Nasopharyngeal NeoplasmsLast Updated:February 16, 2012Completed
Nasopharyngeal Neoplasms: 707 Clinical Trials, Page 1 of 71
Hide Studies Not Open or Pending
2
A Trial of Endostar in Patients With Carcinoma of the Head and Neck
Condition(s):Nasopharyngeal NeoplasmsLast Updated:January 31, 2019Unknown status
3
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal NeoplasmsLast Updated:June 24, 2020Completed
4
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Condition(s):Nasopharyngeal NeoplasmsLast Updated:December 10, 2013Completed
5
Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function
Condition(s):Nasopharyngeal NeoplasmsLast Updated:February 9, 2010Completed
6
Intensity Modulated Radiation Therapy for Head and Neck Cancer
Condition(s):Nasopharyngeal NeoplasmsLast Updated:December 2, 2019Completed
7
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal NeoplasmsLast Updated:March 6, 2023Not yet recruiting
8
Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal NeoplasmsLast Updated:June 25, 2020Not yet recruiting
9
Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal NeoplasmsLast Updated:March 28, 2017Unknown status
10
Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal NeoplasmsLast Updated:March 7, 2023Active, not recruiting